Cargando…
Synergistic action of WDR5 and HDM2 inhibitors in SMARCB1-deficient cancer cells
Rhabdoid tumors (RT) are rare and deadly pediatric cancers driven by loss of SMARCB1, which encodes the SNF5 component of the SWI/SNF chromatin remodeler. Loss of SMARCB1 is associated with a complex set of phenotypic changes including vulnerability to inhibitors of protein synthesis and of the p53...
Autores principales: | Florian, Andrea C, Woodley, Chase M, Wang, Jing, Grieb, Brian C, Slota, Macey J, Guerrazzi, Kiana, Hsu, Chih-Yuan, Matlock, Brittany K, Flaherty, David K, Lorey, Shelly L, Fesik, Stephen W, Howard, Gregory C, Liu, Qi, Weissmiller, April M, Tansey, William P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8892060/ https://www.ncbi.nlm.nih.gov/pubmed/35252869 http://dx.doi.org/10.1093/narcan/zcac007 |
Ejemplares similares
-
WDR5 is a conserved regulator of protein synthesis gene expression
por: Bryan, Audra F, et al.
Publicado: (2020) -
Impact of WIN site inhibitor on the WDR5 interactome
por: Guarnaccia, Alissa D., et al.
Publicado: (2021) -
Inhibition of MYC by the SMARCB1 tumor suppressor
por: Weissmiller, April M., et al.
Publicado: (2019) -
WIN site inhibition disrupts a subset of WDR5 function
por: Siladi, Andrew J., et al.
Publicado: (2022) -
Targeting WDR5: A WINning Anti-Cancer Strategy?
por: Aho, Erin R, et al.
Publicado: (2019)